Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Risk Markers of Arterial Aging. The Paris Prospective Study III-2

NCT06079424 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-06-20
Last updated
2026-09-17

Condition(s) studied

Arterial Stiffness

Investigational drug(s) / intervention(s)

high-precision carotid echo-tracking

high-precision carotid echo-tracking: evaluation of vascular aging parameters and baroreflex sensitivity

Study summary

The main objectives of PPS3-2 are (i) to describe the dynamics of vascular aging and baroreflex sensitivity 12 to 16 years a part, (ii) to identify their determinants, and (iii) to quantify the subsequent risk of cardiovascular diseases.

Eligibility

Sex
ALL
Min age
60 Years
Max age
95 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Being enrolled in PPS3 and having signed an informed consent for PPS3-2 Exclusion Criteria: * Institutionalized participants * Participants under guardianship * Participants under judicial safeguard measure

Primary outcome measure(s)

  • carotid diameter — by 2027
    high precision carotid echo tracking diameter in mm
  • intima media thickness — by 2027
    high precision echo tracking intima media thickness of the common carotid artery in mm
  • carotid plaques — by 2027
    high precision carotid echo tracking carotid plaques
  • wall cross sectional area — by 2027
    high precision carotid echo tracking carotid wall cross sectional area, mm2
  • distensibility coefficient — by 2027
    high precision carotid echo tracking distensibility coefficient in 10-3/kPa
  • elastic modulus — by 2027
    high precision carotid echo tracking Young's elastic modulus, 10-3\*kPa
  • pulse wave velocity — by 2027
    high precision carotid echotracking pulse wave velocity, m/s
  • carotid wall stress — by 2027
    high precision carotid echotracking circumferential wall stress in kPa
  • stiffness — by 2027
    high precision carotid echotracking Beta stiffness index
  • pulse pressure — by 2027
    high precision carotid echotracking pulse pressure in mmHg

Trial sites (1)

FacilityCityRegionStatus
Centre d'Investigation Précliniques Paris France Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06079424 on ClinicalTrials.gov ↗ ← All trials in France